Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides. / Miroshnichenko, Svetlana; Patutina, Olga; Almieva, Olga и др.
в: International Journal of Molecular Sciences, Том 27, № 12, 5446, 17.06.2026.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides
AU - Miroshnichenko, Svetlana
AU - Patutina, Olga
AU - Almieva, Olga
AU - Burakova, Ekaterina
AU - Maslov, Mikhail
AU - Fokina, Alesya
AU - Stetsenko, Dmitry
AU - Zenkova, Marina
N1 - Miroshnichenko, S.; Patutina, O.; Almieva, O.; Burakova, E.; Maslov, M.; Fokina, A.; Stetsenko, D.; Zenkova, M. Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides. Int. J. Mol. Sci. 2026, 27, 5446. https://doi.org/10.3390/ijms27125446 This research was funded by the Russian Science Foundation, grant #25-14-00171 and the Russian state-funded project for ICBFM SB RAS #125012300659-6.
PY - 2026/6/17
Y1 - 2026/6/17
N2 - Molecular heterogeneity of malignant tumours remains a central challenge in oncology. Although neoplasms of distinct histogenesis share core oncogenic properties, the signalling networks sustaining these phenotypes are tumour-specific, highlighting the need for regulatory-level therapeutics adaptable to distinct molecular contexts. Oncogenic microRNAs (miRNAs), among which miR-21, miR-17, and miR-155 are broadly overexpressed in epithelial, lymphoid, and glial-neuronal neoplasms, represent attractive targets for therapeutic intervention. MiRNA inhibition by antisense oligonucleotides has emerged as a promising therapeutic strategy, and mesyl (methanesulfonyl) phosphoramidate oligonucleotides (µ-AMOs) represent a next-generation class of anti-miRNA agents with superior nuclease resistance and biological activity. Here, we report a systematic screening of 23 tumour cell lines of diverse histogenesis for sensitivity to paired combinations of µ-AMOs targeting miR-21, miR-17, and miR-155. Epithelial-derived lines exhibited the highest responsiveness, while lymphoid cell lines demonstrated the lowest sensitivity. The efficacy of specific µ-AMO pairs was found to be cell type-specific: combinations containing miR-21-targeting µ-AMO were most effective in epithelial lines, whereas the miR-17/miR-155-targeting pair showed superior activity in neuroglial models. Cellular responsiveness was driven by the extent of miRNA suppression, with no correlation detected for delivery efficiency or basal miRNA levels. The obtained results provide a basis for tumour-type-specific selection of µ-AMO combinations for clinical translation.
AB - Molecular heterogeneity of malignant tumours remains a central challenge in oncology. Although neoplasms of distinct histogenesis share core oncogenic properties, the signalling networks sustaining these phenotypes are tumour-specific, highlighting the need for regulatory-level therapeutics adaptable to distinct molecular contexts. Oncogenic microRNAs (miRNAs), among which miR-21, miR-17, and miR-155 are broadly overexpressed in epithelial, lymphoid, and glial-neuronal neoplasms, represent attractive targets for therapeutic intervention. MiRNA inhibition by antisense oligonucleotides has emerged as a promising therapeutic strategy, and mesyl (methanesulfonyl) phosphoramidate oligonucleotides (µ-AMOs) represent a next-generation class of anti-miRNA agents with superior nuclease resistance and biological activity. Here, we report a systematic screening of 23 tumour cell lines of diverse histogenesis for sensitivity to paired combinations of µ-AMOs targeting miR-21, miR-17, and miR-155. Epithelial-derived lines exhibited the highest responsiveness, while lymphoid cell lines demonstrated the lowest sensitivity. The efficacy of specific µ-AMO pairs was found to be cell type-specific: combinations containing miR-21-targeting µ-AMO were most effective in epithelial lines, whereas the miR-17/miR-155-targeting pair showed superior activity in neuroglial models. Cellular responsiveness was driven by the extent of miRNA suppression, with no correlation detected for delivery efficiency or basal miRNA levels. The obtained results provide a basis for tumour-type-specific selection of µ-AMO combinations for clinical translation.
KW - anti-miRs
KW - antisense oligonucleotides
KW - cancer
KW - epithelial tumour cells
KW - lymphoid tumour cells
KW - mesyl phosphoramidate
KW - miR-155
KW - miR-17
KW - miR-21
KW - neuronal tumour cells
KW - рак
KW - эпителиальные опухолевые клетки
KW - нейрональные опухолевые клетки
KW - лимфоидные опухолевые клетки
KW - антисмысловые олигонуклеотиды
KW - анти-микроРНК
KW - miR-21
KW - miR-17
KW - miR-155
KW - мезилфосфорамидат
UR - https://www.mendeley.com/catalogue/1174a743-dc53-310f-82d7-73ab343f2583/
UR - https://www.scopus.com/pages/publications/105043086158
U2 - 10.3390/ijms27125446
DO - 10.3390/ijms27125446
M3 - Article
C2 - 42353165
VL - 27
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 12
M1 - 5446
ER -
ID: 85413440